Prima BioMed Ltd (PBMD) Announces Positive Data from CAN-003 Phase II in Ovarian Cancer
Tweet Send to a Friend
Prima BioMed Ltd (NASDAQ: PBMD) announced that the final CVac data from the Phase II CAN-003 ovarian cancer clinical trial ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE